Analogue-Based Drug Discovery II / Edition 1

Hardcover (Print)
Used and New from Other Sellers
Used and New from Other Sellers
from $159.51
Usually ships in 1-2 business days
(Save 30%)
Other sellers (Hardcover)
  • All (7) from $159.51   
  • New (6) from $159.51   
  • Used (1) from $169.64   

Overview

Born out of a project of the IUPAC's committee on Medicinal Chemistry and Drug Development, this reference addresses past and current strategies for successful drug analog development, extending the previously published volume by nine new analog classes and eight case studies. Like its precursor, this volume also contains a general section discussing universally applicable strategies for analog discovery and development. Spanning a wide range of therapeutic fields and chemical classes, the two volumes together constitute the first systematic approach to drug analog development.
Of interest to virtually every researcher working in drug discovery and pharmaceutical chemistry.

Read More Show Less

Editorial Reviews

From the Publisher
"Analogue-Based Drug Discovery II is a companion book to the first volume ... This volume provides an excellent overview of several biological targets, compound classes, and illustrations of problem solving in medicinal chemistry for chemists in drug discovery who are beginning to establish their careers" (ChemMedChem, 1 January 2012)
Read More Show Less

Product Details

  • ISBN-13: 9783527325498
  • Publisher: Wiley
  • Publication date: 9/14/2010
  • Edition number: 1
  • Pages: 564
  • Sales rank: 1,303,577
  • Product dimensions: 6.80 (w) x 9.60 (h) x 1.20 (d)

Meet the Author

János Fischer is a Senior Research Scientist at Richter Plc., Budapest, Hungary. He received his MSc and PhD degrees in organic chemistry from the Eotvos University of Budapest under Professor A. Kucsman. Between 1976 and 1978, he was a Humboldt Fellow at the University of Bonn under Professor W. Steglich. He has worked at Richter Plc. since 1981 where he participated in the research and development of leading cardiovascular drugs in Hungary. His main interest is analogue based drug discovery. He is the author of some 100 patents and scientific publications. In 2004, he was elected as a Titular member of the Chemistry and Human Health Division of IUPAC. He received an honorary professorship at the Technical University of Budapest.

C. Robin Ganellin studied Chemistry at London University, receiving a PhD in 1958 under Professor Michael Dewar, and was a Research Associate at MIT with Arthur Cope in 1960. He then joined Smith Kline & French Laboratories in the UK and was one of the co inventors of the revolutionary drug, cimetidine (also known as Tagamet). In 1986, he was made a Fellow of the Royal Society and appointed to the SK&F Chair of Medicinal Chemistry at University College London, where he is now Professor Emeritus of Medicinal Chemistry. Professor Ganellin is co inventor of over 160 patents and has authored over 260 scientific publications. He was President of the Medicinal Chemistry Section of the IUPAC and is Chairman of the IUPAC Subcommittee on Medicinal Chemistry and Drug Development.

Read More Show Less

Table of Contents

PART I GENERAL ASPECTS
Optimizing Drug Therapy by Analogues
Standalone Drugs
Application of Molecular Modeling in Analogue-Based Drug Discovery
Issues for the Patenting of Analogues

PART II ANALOGUE CLASSES
Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
Rifamycins, Antibacterial Antibiotics and Their New Applications
Monoterpenoid Indole Alkaloids, CNS Anticancer Drugs
Anthracyclines, Optimizing Anticancer Analogues
Paclitaxel and Epothilone Analogues, Anticancer Drugs
Selective Serotonin Reuptake Inhibitors for the Treatment of Depression
Muscarinic Receptor Antagonists in the Treatment of COPD
beta-Adrenoceptor Agonists and Asthma

PART III CASE HISTORIES
Liraglutide, a GLP-1 Analogue to Treat Diabetes
Eplerenone: Selective Aldosterone Antagonist
Clevudine, to Treat Hepatitis B Viral Infection
Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1
Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV
Lapatinib, an Anticancer Kinase Inhibitor
Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia
Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)